Major Study Shows MabThera(R), an Innovative B Cell Therapy, to be Highly Effective in Treating Rheumatoid Arthritis
Results from the DANCER study presented today revealed that MabThera significantly improves symptoms in heavily treated patients who are affected by moderate-to-severe rheumatoid arthritis (RA), a painful and debilitating disease of the joints.
Arrowhead Licenses Nanotech Stem Cell Device From Stanford
Arrowhead Research has exclusively licensed intellectual property from Stanford University for a nanotech device that controls the behavior of adult stem cells.
Cell Genesys, Inc. (CEGE) Announces Strategic Restructuring of Business To Focus On Most Advanced Programs; Close Plant, Cut 95 Jobs
Cell Genesys, Inc. today announced that it is implementing a strategic restructuring of its business operations to focus resources on its most advanced and most promising product development programs.
CellGenix registers FDA Drug Master Files for ex-vivo CellGro(R) TNF-alpha and GM-CSF
After filing a DMF for IL-4, this contributes further to the strategy of producing highest quality cytokines for the use in clinical ex-vivo cell culturing in connection with cell processing kits.
IDM’s European Manufacturing Facilities Have Been Granted “Cell Therapy Establishment” Designation by the French Drug Agency, Afssaps
IDM is the first private company in France to receive this designation, which authorizes the company to perform activities in the preparation, storage, distribution and transfer of cell therapy products.
Publications in Molecular Therapy Identify Molecular Pathways Underlying Activity of Introgen’s INGN 241 Anti-Cancer Therapy
Researchers at Introgen Therapeutics, Inc. (Nasdaq: INGN – News) and The University of Texas M. D. Anderson Cancer Center have identified the molecular pathways by which mda-7, the active component of INGN 241, induces growth arrest and programmed cell death (apoptosis) in cancer cells.
MultiCell Technologies Commences Sales of Immortalized Porcine Hepatocytes
MultiCell Technologies, Inc. a leading supplier of immortalized human hepatic cell lines for pharmaceutical candidate optimization, announced today that it has commenced sales of HepLiu immortalized porcine (pig) hepatocytes and porcine media dry powder.
Neurologix Completes Procedures in Landmark Phase I Gene Therapy Trial; Co-Founder Presents Trial Update at Parkinson’s Disease Conference
Neurologix, Inc. today announced the completion of all neurosurgical gene transfer procedures in its landmark, 12-patient, dose-escalating Phase I clinical trial of gene therapy for Parkinson’s disease.
Osiris Therapeutics, Inc. Raises $50 Million To Commercialize First Stem Cell Products; Proceeds Will Advance Three Promising Treatments Currently In Human Trials
The financing will fund the company’s three ongoing clinical trial programs using their proprietary adult stem cell technology platform.
Pegasus Biologics Inc. Raises $10M in Series B Financing; Breakthrough Technologies Create “Intelligent Bioimplants” for Orthopedic Soft Tissue Repair
Pegasus Biologics has licensed patented technologies from Biomedical Design that the Company is utilizing to develop advanced bioimplants.
Progenitor Cell Therapy, LLC Welcomes Dr. Onyenoha Chukwumerije as Vice President, Quality Systems
Progenitor Cell Therapy, LLC is pleased to announce that Dr. Onyenoha “Chuck” Chukwumerije has joined the Company’s Executive Management Team as Vice President, Quality Assurance.
StemCell Technologies Signs Worldwide Distribution Deal for ALDEFLUOR™ with StemCo Biomedical
StemCell Technologies, Inc. today announced that it has signed a worldwide distribution agreement with StemCo Biomedical, Inc. whereby StemCell Technologies will distribute StemCo’s ALDEFLUOR™ product.
Thomas Schreck Named CEO of Iken Tissue Therapeutics
Iken President Michael Siani-Rose presented Mr. Schreck to shareholders at the company’s annual meeting on Thursday, June 9, 2005 in San Francisco. Mr. Schreck most recently served as Chief Financial Officer and Director of DURECT Corporation, an emerging specialty pharmaceutical company he co-founded in 1998.
Vical Incorporated Licenses Three Cancer Vaccine Targets To Merck & Co., Inc.
Vical Incorporated announced today that Merck & Co., Inc. has exercised three options under a 2003 amendment to an existing research collaboration and license agreement, granting Merck rights to use Vical’s patented non-viral gene delivery technology in cancer vaccine applications.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents